NFKB1 and glioblastoma: Together with the in vitro data that lovastatin can enhance TRAIL-mediated apoptosis through up-regulation of DR5 as well as inhibition of NF-κB pathway, our results provided molecular basis and pre-clinical evidence that lovastatin potentiates efficacy of TRAIL-based therapy for the treatment of human glioblastoma.